SNTI vs. VTGN, IMAB, PYRGF, THTX, ADAG, ANL, PMVP, EPIX, MURA, and TLSA
Should you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Vistagen Therapeutics (VTGN), I-Mab (IMAB), PyroGenesis Canada (PYRGF), Theratechnologies (THTX), Adagene (ADAG), Adlai Nortye (ANL), PMV Pharmaceuticals (PMVP), ESSA Pharma (EPIX), Mural Oncology (MURA), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry.
Senti Biosciences vs.
Vistagen Therapeutics (NASDAQ:VTGN) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.
Vistagen Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500.
78.4% of Vistagen Therapeutics shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 1.3% of Vistagen Therapeutics shares are held by company insiders. Comparatively, 10.7% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Vistagen Therapeutics received 278 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 40.00% of users gave Senti Biosciences an outperform vote.
Senti Biosciences has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -6,777.08%. Vistagen Therapeutics' return on equity of -48.12% beat Senti Biosciences' return on equity.
In the previous week, Vistagen Therapeutics had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 1 mentions for Vistagen Therapeutics and 0 mentions for Senti Biosciences. Vistagen Therapeutics' average media sentiment score of 0.01 beat Senti Biosciences' score of 0.00 indicating that Vistagen Therapeutics is being referred to more favorably in the media.
Senti Biosciences has a consensus price target of $10.00, suggesting a potential upside of 152.53%. Given Senti Biosciences' higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Vistagen Therapeutics.
Vistagen Therapeutics has higher earnings, but lower revenue than Senti Biosciences. Vistagen Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Vistagen Therapeutics beats Senti Biosciences on 12 of the 19 factors compared between the two stocks.
Get Senti Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senti Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:SNTI) was last updated on 2/22/2025 by MarketBeat.com Staff
Free SNTI Stock Alerts